Comparative Metabolic

GLP-1 Dual Agonist

Head-to-head incretin comparison

Pairs the two leading GLP-1 pathway agonists for comparative metabolic research. Semaglutide provides pure GLP-1 receptor activation while Tirzepatide adds dual GIP/GLP-1 engagement, enabling direct mechanistic comparison studies.

2Components
10% OFFBundle Savings
You save $8.89
Bundle Price
$88.90$80.01
Save $8.89 (10% off)
$46.95
$41.95
Individual Total$88.90
Stack Price$80.01
Add Full Stack to Cart

All components ship together with individual COA documentation

COA Included
HPLC Verified
Same-Day Ship
Research Rationale

How These Work Together

Semaglutide provides pure GLP-1 receptor agonism with a 7-day half-life, enabling sustained incretin pathway activation. Tirzepatide adds GIP receptor co-agonism, engaging a second metabolic pathway that enhances insulin sensitivity and lipid metabolism beyond what GLP-1 alone achieves. Running both compounds enables direct comparison of single vs. dual incretin engagement in the same research model.

Ready to Start This Protocol?

Order the complete GLP-1 Dual Agonist stack at $80.01 and save $8.89 versus buying each component individually.